Business Description
Kazia Therapeutics Ltd
ISIN : US48669G3039
Share Class Description:
KZIA: ADRTotal Employee Number:
6Description
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 699.29 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -36.2 | |||||
Beneish M-Score | 24.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 49.8 | |||||
3-Year EPS without NRI Growth Rate | 48.4 | |||||
3-Year FCF Growth Rate | 49.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 35.53 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 229.84 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.06 | |||||
9-Day RSI | 35.78 | |||||
14-Day RSI | 40.95 | |||||
3-1 Month Momentum % | 19.33 | |||||
6-1 Month Momentum % | 94.81 | |||||
12-1 Month Momentum % | 46.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.87 | |||||
Quick Ratio | 2.87 | |||||
Cash Ratio | 2.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -79.9 | |||||
Shareholder Yield % | -38.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -44981.48 | |||||
Net Margin % | -55600 | |||||
EBITDA Margin % | -44981.48 | |||||
FCF Margin % | -35196.3 | |||||
OCF Margin % | -35196.3 | |||||
ROE % | -195.31 | |||||
ROA % | -72.01 | |||||
ROIC % | -126.85 | |||||
3-Year ROIIC % | -52.12 | |||||
ROCE % | -136.26 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 611 | |||||
PB Ratio | 4.49 | |||||
Price-to-Tangible-Book | 4.59 | |||||
EV-to-EBIT | -7.71 | |||||
EV-to-EBITDA | -7.71 | |||||
EV-to-Revenue | 3466.22 | |||||
EV-to-Forward-Revenue | 109.18 | |||||
EV-to-FCF | -9.85 | |||||
| Price-to-Net-Current-Asset-Value | 4.59 | |||||
| Price-to-Net-Cash | 4.65 | |||||
Earnings Yield (Greenblatt) % | -12.97 | |||||
FCF Yield % | -6.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KZIA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kazia Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.027 | ||
| EPS (TTM) ($) | -6.974 | ||
| Beta | 3.1002 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.19 | ||
| Volatility % | 113.1 | ||
| 14-Day RSI | 40.95 | ||
| 14-Day ATR ($) | 1.091127 | ||
| 20-Day SMA ($) | 13.455 | ||
| 12-1 Month Momentum % | 46.89 | ||
| 52-Week Range ($) | 4.86 - 17.4 | ||
| Shares Outstanding (Mil) | 11.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kazia Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kazia Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-11-06 | In 102 days | ||
| General meeting for 2025 | 2026-03-26 09:00 | 7.30 (+3.55%) | ||
| Second quarter earnings results for 2026 | 2026-03-16 | 7.49 (-4.95%) | ||
| Annual report for 2025 | 2025-11-07 | 7.50 (-3.60%) | ||
| Second quarter earnings results for 2025 | 2025-06-10 | 5.30 (-2.15%) | ||
| General meeting for 2024 | 2025-05-22 10:00 | 3.45 (+1.47%) | ||
| 0.2:1 Stock Split | 2025-04-17 | 3.54 (+1.13%) | ||
| Annual report for 2024 | 2024-11-22 | 27.65 (-1.78%) | ||
| 0.1:1 Stock Split | 2024-10-28 | 26.00 (-1.89%) | ||
| 0.25:1 Stock Split | 2017-07-14 | 172.02 (+7.30%) |
Show
Entries
Kazia Therapeutics Ltd Frequently Asked Questions
What is Kazia Therapeutics Ltd(KZIA)'s stock price today?
The current price of KZIA is $12.22. The 52 week high of KZIA is $17.40 and 52 week low is $4.86.
When is next earnings date of Kazia Therapeutics Ltd(KZIA)?
The next earnings date of Kazia Therapeutics Ltd(KZIA) is 2027-03-16 Est..
Does Kazia Therapeutics Ltd(KZIA) pay dividends? If so, how much?
Kazia Therapeutics Ltd(KZIA) does not pay dividend.
Guru Commentaries on NAS:KZIA
No articles.
Press Release
Articles on Kazia Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers